Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이정연 | * |
dc.contributor.author | 강지은 | * |
dc.date.accessioned | 2020-12-24T16:30:11Z | - |
dc.date.available | 2020-12-24T16:30:11Z | - |
dc.date.issued | 2020 | * |
dc.identifier.issn | 0269-4727 | * |
dc.identifier.issn | 1365-2710 | * |
dc.identifier.other | OAK-28464 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/255805 | - |
dc.description.abstract | What is known and Objective Understanding investigational medications is important. Many older drugs are being investigated for repurposing against COVID-19. We comment on various drugs currently undergoing such trials to optimize their safe use. Comment We describe medications used during early COVID-19 outbreaks in South Korea, focusing on practice aspects including the method of drug administration, drug formulation, patient-monitoring for adverse reactions and drug interactions informed by our experience during the 2015 outbreak of Middle East respiratory syndrome (MERS). We comment on hydroxychloroquine, chloroquine, lopinavir/ritonavir with zinc supplement, remdesivir, tocilizumab, ciclesonide, niclosamide and high-dose intravenous immunoglobulin (IVIG). What is new and conclusion Effective therapies are urgently needed to manage COVID-19, and existing drugs such as antivirals and antimalarials are under investigation for repurposing to meet this need. This process requires up-to-date drug information to ensure optimum use, particularly safety and efficacy profiles of the medications, until convincing evidence is reported. | * |
dc.language | English | * |
dc.publisher | WILEY | * |
dc.subject | COVID-19 | * |
dc.subject | investigational medication | * |
dc.subject | SARS-CoV-2 | * |
dc.subject | severe acute respiratory syndrome | * |
dc.title | Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 45 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1199 | * |
dc.relation.lastpage | 1205 | * |
dc.relation.journaltitle | JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS | * |
dc.identifier.doi | 10.1111/jcpt.13199 | * |
dc.identifier.wosid | WOS:000539277500001 | * |
dc.author.google | Kang, Ji Eun | * |
dc.author.google | Rhie, Sandy Jeong | * |
dc.contributor.scopusid | 이정연(57191753089) | * |
dc.contributor.scopusid | 강지은(57155481300) | * |
dc.date.modifydate | 20240220111424 | * |